Loren Data's SAM Daily™

FBO DAILY ISSUE OF NOVEMBER 02, 2002 FBO #0335
SOLICITATION NOTICE

66 -- Automated Laser Capture Microdissection Instrument

Notice Date

10/31/2002
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-30008-NG
 

Archive Date

11/30/2002
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, cr214i@nih.gov
 

Description

The National Cancer Institute (NCI), Division of Clinical Sciences (DCS), Laboratory of Pathology (LP) plans to procure an AutoPix 110V for the FDA-NCI Joint Clinical Proteomics Initiative from Arcturus Engineering, Inc., 400 Logue Avenue, Mountain View, CA 94043. The supplies and services herein are commercial as defined in FAR Part 12, and this acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items as authorized in FAR Part 13. The North American Industry Classification System code is 334516 and the business size standard is 500. The primary focus of the "Clinical Proteomics Initiative" (CPI) that exists between the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) and the Center for Cancer Research (CCR) and the National Cancer Institute (NCI) is the advancement of common research interests shared by CBER and NCI in the application and development of proteomic technology to the diagnosis and treatment of human cancer, development of proteomic tools that can detect and predict therapeutic efficacy and toxicity, further evaluate licensed and experimental drugs and biologics, and build upon the work emanating from the CPI. Laser Capture Microdissection was invented in the laboratory as a method for isolating specific cells within a complex tissue section for DNA, RNA and proteomic analysis. This approach has enabled NCI to isolate normal, pre-malignant and malignant cell populations for the proteomic analysis of pro-survival and pro-death pathways. This technology has been applied to the effectiveness of clinical trials, gene expression, and vaccine validation. The existing equipment (PixCell II and PixCell IIe models) utilizes a manual method of microdisscetion, utilizing an inverted light microscope with a near infra-red laser. This low temperature laser limits damage to nucleic acids and proteins. This initiative is to further develop and enhance the methodology used for screening molecular markers and pathway targets in human tissue during disease progression. Minimum Requirements: 1) solid state near infra-red laser and thermoplastic film for embedding the cells. The laser is pulsed and shall last approximately 50 years; 2) no special tissue mounting or slide preparation required. LCM is performed on fixed tissue sections, frozen tissue sections or fixed cytological smears and cell cultures; 3) shall incorporate a completely enclosed design with integrated fluorescence microdissection capabilities and; 4) shall allow standardization and consistency in microdissection of clinical trial tissue, aiding in the evaluation of potential cancer treatments. Arcturus Engineering, Inc. is the only source known to the NCI that can meet the aforementioned requirements. Also, the AutoPix 110V is the only system known that is available to accommodate and process up to 3 slides automatically in a single session as well as the only system available with automatic cell recognition software. In addition, Arcturus Engineering is the only source known with a patented near infra-red laser and thermoplastic film for embedding cells. This is not a request for competitive quotations. However, if any interested party believes it can perform the above requirements, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above minimum specifications described herein. Capability statements must be received in the Contracting Office by 1:00 PM EST (local Washington D.C. time) on November 15, 2002. If you have any questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@exchange.nih.gov or by fax at (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. Faxed copies of capability statements will not be accepted. All interested parties are to submit one (1) original and two (2) copes to the following address: Malinda Holdcraft, Purchasing Agent, NIH/NCI/RCB, 6120 Executive Blvd. Room 6072, Rockville, Maryland 20852-7194.
 

Place of Performance

Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD 20892

Zip Code: 20892

Country: USA
 

Record

SN00196989-W 20021102/021101073732 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |